Drug profile

Compounded semaglutide (semaglutide): the 2026 buyer's guide

Compounded semaglutide is the same active molecule as Wegovy and Ozempic, prepared by a 503A pharmacy under prescription rather than manufactured under FDA new-drug approval. Cash-pay savings versus branded are typically 50-80%. The regulatory environment has tightened since the FDA declared the semaglutide shortage resolved. Below: how it works, what it costs, what's changed in 2025-2026 and which programs still offer it responsibly.

Compare Compounded semaglutide prices →

Key takeaways

Compounded semaglutide is a weekly injection, prepared by 503A pharmacies under prescription, not FDA-approved as a drug product.
In the STEP-1 (parent molecule, Wegovy) trial, mean weight loss was 14.9% over 68 weeks, with 50.5% of patients losing 15% or more of body weight.
It carries the GLP-1 class boxed warning for thyroid C-cell tumor risk, and is not for people with a personal or family history of medullary thyroid carcinoma or MEN2.
Cash, insurance and compounded prices differ widely. See the cost breakdown below, and the all-in program costs on the chart.

Active ingredient

semaglutide

Manufacturer

503A pharmacies (varies by program)

Regulatory status

Not FDA-approved as a drug product. Prepared under prescription per section 503A of the FD&C Act.

Schedule

Weekly · subcutaneous injection (vial, prepared at the pharmacy)

What Compounded semaglutide costs in 2026

There is no one price. What you pay depends on which path you take:

Retail cash

Not sold at retail; cash-pay through telehealth programs only

Compounded medications are not sold at retail pharmacies; this path does not apply.

Telehealth cash-pay

$169-$199/mo via telehealth programs (Mochi $178 flat month-to-month, Found $169 on a 12-month plan, Noom microdose $199). Strut Health at $99 is an oral lozenge, not an injectable.

Cash-pay through a telehealth program working with a 503A pharmacy. There is no manufacturer cash channel for a compounded drug.

Insurance + prior auth

Not covered by insurance. Compounded medications are not eligible for insurance reimbursement as drug products.

Compounded medications are generally not eligible for insurance reimbursement as drug products.

Compounded (503A)lowest cash

Cash-pay only by definition. Pricing varies from $169/mo (Found, 12-month commitment) and $178/mo month-to-month (Mochi) up to $299/mo depending on program.

Same molecule from a compounding pharmacy. Cheapest path, most regulatory risk.

Telehealth programs add a membership fee on top of the medication cost (typically $40-$200/mo). For all-in monthly costs by program, see the chart, the full GLP-1 cost guide, or calculate your exact all-in cost by drug, coverage and state.

Who it's for

Same prescribing audience as Wegovy in practice (BMI ≥30, or BMI ≥27 with comorbidity), though the prescription is for a compounded product rather than the FDA-approved branded version.

What the trials show

Compounded semaglutide's registration trial was STEP-1 (parent molecule, Wegovy) (NEJM, 2021). At 68 weeks at the maximum dose, mean weight loss was 14.9% (12.4 percentage points greater than placebo). 86.4% of patients lost at least 5% of body weight; 50.5% lost at least 15%. Real-world results vary; trial patients are typically more adherent and more closely managed than typical telehealth patients.

Dose schedule

Dose levels: 0.25mg, 0.5mg, 1.0mg, 1.7mg, 2.4mg. Standard practice is to titrate up monthly, holding at any tolerated dose. Maximum dose is Typically titrated to 2.0-2.4mg weekly to mirror Wegovy; many patients reach goal weight at sub-maximum doses and stay there.

Common side effects

The most commonly reported side effects in the registration trial:

Same profile as branded semaglutide; nausea, diarrhea, constipation, vomiting most common
Real-world reports of injection-site reactions occasionally vary by 503A pharmacy
Rare reports of dosing inconsistency between batches and pharmacies

Boxed warning: Same class warning as branded semaglutide. Compounded preparations are not subject to FDA's full new-drug-approval safety review; sterility and potency rely on the 503A pharmacy's state-board oversight and program-level quality controls.

How Compounded semaglutide differs from related drugs

Same molecule as Wegovy at typical compounded doses. Cheaper. Not FDA-approved as a drug product (the molecule is FDA-approved only as the branded versions). Insurance does not cover. Regulatory exposure has increased through 2025-2026 but compounded semaglutide supply has held up better than compounded tirzepatide.

Programs that prescribe Compounded semaglutide

These programs in our chart prescribe Compounded semaglutide (with insurance coverage where applicable, or as a cash-pay option). Ranked by overall score.

Some visit links earn us a commission.

Compounded semaglutide vs other GLP-1s

Learn more about Compounded semaglutide

References

Trial figures are mean results at the maximum dose in the cited registration trial. Real-world outcomes vary with adherence and clinical management.

Editorial disclosure

GLP Chart is an editorial comparison site. We do not dispense, prescribe or fulfill medications. Talk to a licensed clinician about whether Compounded semaglutide is appropriate for you. Pricing reflects publicly verified rates as of June 22; verify with the manufacturer or your prescriber before committing.

John Samaras, Founder and EditorI started GLP Chart after overpaying for a GLP-1 myself. Based in Austin, Texas.
About this site · LinkedIn · Contact

Why you can trust GLP ChartSame scoring framework applied to every program. No paid placements. We never remove unfavorable information at an advertiser's request. Pricing is pulled from each program's public-facing page every Monday.